Cargando…
ASO Visual Abstract: Effectiveness of a Short Duration of Neoadjuvant Endocrine Therapy in Patients with HR+ Breast Cancer—An NCDB Analysis (2004–2016)
Autores principales: | Goldbach, Macy M., Burkbauer, Laura, Bharani, Tina, Williams, Austin D., Keele, Luke, Rothman, Jami, Jankowitz, Rachel, Tchou, Julia C. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Springer International Publishing
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8237557/ http://dx.doi.org/10.1245/s10434-021-10353-y |
Ejemplares similares
-
Effectiveness of a Short Duration of Neoadjuvant Endocrine Therapy in Patients with HR+ Breast Cancer—An NCDB Analysis (2004–2016)
por: Goldbach, Macy M., et al.
Publicado: (2021) -
Correction to: Effectiveness of a Short Duration of Neoadjuvant Endocrine Therapy in Patients with HR+ Breast Cancer—An NCDB Analysis (2004–2016)
por: Goldbach, Macy M., et al.
Publicado: (2021) -
ASO Author Reflections: Objective Response Rate after Short Duration (< 9 Weeks) Is Not Inferior to Moderate (9–27 Weeks) or Long Duration (> 27 Weeks) of Neoadjuvant Endocrine Therapy (NET)—An NCDB Analysis
por: Burkbauer, Laura, et al.
Publicado: (2021) -
ASO Visual Abstract: Surgical Management of Axilla Following Neoadjuvant Endocrine Therapy
por: Murphy, Brenna M., et al.
Publicado: (2021) -
ASO Visual Abstract: Neoadjuvant Endocrine Therapy and Delays in Surgery for Ductal Carcinoma in Situ: Implications for the Coronavirus Pandemic
por: Williams, Austin D., et al.
Publicado: (2021)